We are monitoring the impact of COVID-19 on North America Ophthalmic Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 5300
Share on
Share on

North America Ophthalmic Drugs Market Research Report - Segmented By Therapeutic Class, Product Type, Distribution Channel, Disease Indication, Dosage Form, Technology and Country (the United States, Canada and Rest of North America) - Industry Analysis, Size, Share, Trends and Growth Forecast (2020 to 2025)

Pulished: February, 2020
ID: 5300
Pages: 145

North America Ophthalmic Drugs Market Size (2020 to 2025)

As per the research report, the North America Ophthalmic Drugs market size is valued at around USD 11.62 billion in 2020. It is expected to grow at a CAGR of 4.7% to reach USD 14.62 billion by 2025. It captures 35% of the global market.

Y-O-Y growth in the incidence of eye-related diseases such as macular degeneration and diabetic retinopathy among the growing aging population is a crucial factor driving the ophthalmic drugs market in North America. Increasing cases for glaucoma and dry eyes, rising awareness levels, new medical requirements, and growing cataract in people are considered to fuel the market growth in the coming years. The number of people suffering from diabetic retinopathy in the U.S. is expected to increase from 7.7 million in 2010 to 9.2 million in 2020, which is a positive sign of market growth in this region.

Side-effects associated with ophthalmic drugs and the long-gestation period during the time of advancing the new drugs are significant challenges to the market. Moreover, the high cost of these drugs is also a considerable factor obstructing the market.

This research report on the North America Ophthalmic Drugs Market has been segmented and sub-segmented into the following categories:

  • By Therapeutic Class: Anti-inflammatory Drug, Anti-infective Drugs, Anti-glaucoma Drugs, Anti-allergy Drugs, Anti-VEGF Agents, Others
  • By Product Type: Prescription Drugs, Over-the-Counter Drugs 
  • By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Independent Pharmacies & Drug Stores 
  • By Disease Indications: Dry Eye, Glaucoma, Infection/Inflammation, Retinal Disorders, Allergy, Uveitis, Others  
  • By Dosage Form: Liquid Ophthalmic Drug Forms, Solid Ophthalmic Drug Forms, Semisolid Ophthalmic Drug Forms, Multicompartment Drug Delivery Systems, Other Ophthalmic Drug Forms       
  • By Technology: Biologics, Cell Therapy, Gene Therapy, Drug Delivery, Small molecule, Others 
  • By Country: the United States, Canada, and Rest of North America

Regionally, North America captures the largest share globally due to higher market penetration by the US.

The United States is to lead the market in the region with the largest share of the period. Increasing epitomes of eye-related diseases and resultant vision impairment, which surge the market growth during the period. Numerous approvals of advanced new products and techniques, flourishing patient population who need long-term treatment, are to garnish the market growth during the forecast period. Moreover, the increasing requirement for ophthalmic drugs, most people with vision impairments, which cause uncorrected refractive errors and cataracts in people above 50 years and above, also lifts the market in the ophthalmic drugs market of the North America region.

Canada is projected to have rapid growth in the market during the forecast frame time. This country's evolution is attributed to increasing concentration on research and development activities to enhance innovative treatment, and the existence of key players in the market is to boost the market.

Companies playing a dominant role in the North America Ophthalmic Drugs Market profiled in this report are Carl-Zeiss AG, Ellex Medical Lasers Ltd., Hoya Corporation, Novagali Pharma S A, Abbott Medical Optics, Inc., Essilor International S.A. Other players in the market include Insight Vision Inc., Nidek Co.Ltd, Topcon Corporation, and Ziemer Ophthalmic Systems AG.

1.Introduction          

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods  

                1.4 General Study Assumptions                

2. Research Methodology                   

                2.1 Introduction       

                2.2 Research Phases                      

        2.2.1 Secondary Research           

        2.2.2 Primary Research 

        2.2.3 Econometric Modelling      

        2.2.4 Expert Validation  

                2.3 Analysis Design 

                2.4 Study Timeline  

3. Overview               

                3.1 Executive Summary                

                3.2 Key Inferences 

                3.3 Epidemology      

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)            

                4.1 Market Drivers  

                4.2 Market Restraints                    

                4.3 Key Challenges 

                4.4 Current Opportunities in the Market      

5. Market Segmentation                      

                5.1 Therapeutic Class                     

        5.1.1 Introduction           

        5.1.2 Anti-inflammatory Drugs  

                        5.1.2.1 Nonsteroidal Anti-inflammatory Drugs

                        5.1.2.2 Steroids

        5.1.3 Anti-infective Drugs            

                        5.1.3.1 Anti-fungal Drugs

                        5.1.3.2 Anti-bacterial Drugs

                        5.1.3.3 Others

        5.1.4 Anti-glaucoma Drugs          

                        5.1.4.1 Alpha Agonist

                        5.1.4.2 Beta Blockers

                        5.1.4.3 Prostaglandin Analogs

                        5.1.4.4 Combined Medication

                        5.1.4.5 Others

        5.1.5 Anti-allergy Drugs

        5.1.6 Anti-VEGF Agents

        5.1.7 Others      

        5.1.8 Y-o-Y Growth Analysis, By Therapeutic Class            

        5.1.9 Market Attractiveness Analysis, By Therapeutic Class          

        5.1.10 Market Share Analysis, By Therapeutic Class         

                5.2 Product Type     

        5.2.1 Introduction           

        5.2.2 Prescription Drugs               

        5.2.3 Over-the-Counter Drugs   

        5.2.4 Y-o-Y Growth Analysis, By Product Type    

        5.2.5 Market Attractiveness Analysis, By Product Type  

        5.2.6 Market Share Analysis, By Product Type    

                5.3 Distribution Channel       

        5.3.1 Introduction           

        5.3.2 Hospital Pharmacies            

        5.3.3 Online  Pharmacies              

        5.3.4 Independent Pharmacies & Drug Stores    

        5.3.5 Y-o-Y Growth Analysis, By Distribution Channel      

        5.3.6 Market Attractiveness Analysis, By Distribution Channel    

        5.3.7  Market Share Analysis, By Distribution Channel     

                5.4 Disease Indications                 

        5.4.1 Introduction           

        5.4.2 Dry Eye     

        5.4.3 Glaucoma

        5.4.4 Infection/Inflammation     

        5.4.5 Retinal Disorders  

                        5.4.5.1 Wet Age-related Macular Degeneration

                        5.4.5.2 Dry Age-related Macular Degeneration

                        5.4.5.3 Diabetic Retinopathy

                        5.4.5.4 Others

        5.4.6 Allergy      

        5.4.7 Uveitis      

        5.4.8 Others      

        5.4.9 Y-o-Y Growth Analysis, By Disease Indications         

        5.4.10 Market Attractiveness Analysis, By Disease Indications    

        5.4.11 Market Share Analysis, By Disease Indications      

                5.5 Dosage Form     

        5.5.1 Introduction           

        5.5.2 Liquid Ophthalmic Drug Forms        

        5.5.3 Solid Ophthalmic Drug Forms          

        5.5.4 Semisolid Ophthalmic Drug Forms

        5.5.5 Multicompartment Drug Delivery Systems               

        5.5.6 Other Ophthalmic Drug Forms        

        5.5.7 Y-o-Y Growth Analysis, By Dosage Form     

        5.5.8  Market Attractiveness Analysis, By Dosage Form  

        5.5.9  Market Share Analysis, By Dosage Form   

                5.6 Technology                 

        5.6.1 Introduction           

        5.6.2 Biologics   

        5.6.3 Cell Therapy           

        5.6.4 Gene Therapy       

        5.6.5 Drug Delivery         

        5.6.6 Small molecule      

        5.6.7 Others      

        5.6.8 Y-o-Y Growth Analysis, By Technology        

        5.6.9 Market Attractiveness Analysis, By Technology      

        5.6.10 Market Share Analysis, By Technology     

6. Geographical Analysis                      

                6.1 Introduction       

        6.1.1 Regional Trends    

        6.1.2 Impact Analysis     

        6.1.3 Y-o-Y Growth Analysis        

                        6.1.3.1 By Geographical Area

                        6.1.3.2 By Therapeutic Class

                        6.1.3.3 By Product Type

                        6.1.3.4 By Distribution Channel

                        6.1.3.5 By Disease Indication

                        6.1.3.6 By Dosage Form

                        6.1.3.7 By Technology

        6.1.4  Market Attractiveness Analysis     

                        6.1.4.1 By Geographical Area

                        6.1.4.2 By Therapeutic Class

                        6.1.4.3 By Product Type

                        6.1.4.4 By Distribution Channel

                        6.1.4.5 By Disease Indication

                        6.1.4.6 By Dosage Form

                        6.1.4.7 By Technology

        6.1.5  Market Share Analysis      

                        6.1.5.1 By Geographical Area

                        6.1.5.2 By Therapeutic Class

                        6.1.5.3 By Product Type

                        6.1.5.4 By Distribution Channel

                        6.1.5.5 By Disease Indication

                        6.1.5.6 By Dosage Form

                        6.1.5.7 By Technology

                6.2 United States    

                6.3 Canada

7. Strategic Analysis               

                7.1 PESTLE analysis 

        7.1.1 Political     

        7.1.2 Economic 

        7.1.3 Social         

        7.1.4 Technological         

        7.1.5 Legal          

        7.1.6 Environmental       

                7.2 Porter’s Five analysis      

        7.2.1 Bargaining Power of Suppliers        

        7.2.2 Bargaining Power of Consumers    

        7.2.3 Threat of New Entrants     

        7.2.4 Threat of Substitute Products and Services              

        7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                

                8.1 Abbott Medical Optics, Inc.                 

        8.1.1 Overview 

        8.1.2 Product Analysis   

        8.1.3 Financial analysis  

        8.1.4 Recent Developments       

        8.1.5 SWOT analysis       

        8.1.6 Analyst View          

                8.2 Carl-Zeiss AG     

                8.3 Ellex Medical Lasers Ltd.                       

                8.4 Essilor International S.A.                       

                8.5 Hoya Corporation                    

                8.6 Insight Vision Inc.                     

                8.7 Nidek Co.Ltd      

                8.8 Novagali Pharma S A       

                8.9 Topcon Corporation        

                8.10 Ziemer Ophthalmic Systems AG.                    

9. Competitive Landscape                   

                9.1 Market share analysis    

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures 

                9.4 New Product Launches 

10. Market Outlook and Investment Opportunities                 

Appendix                   

                a) List of Tables                

                b) List of Figures      

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms product type and Packaged Containers along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

 

  1. North America Ophthalmic Drugs Market, By Disease Indication, From 2020 to 2025 (USD Billion)
  2. North America Dry Eye Market, By Region, From 2020 to 2025 (USD Billion)
  3. North America Glaucoma Market, By Region, From 2020 to 2025 (USD Billion)
  4. North America Infection/Inflammation Market, By Region, From 2020 to 2025 (USD Billion)
  5. North America Retinal Disorders Market, By Region, From 2020 to 2025 (USD Billion)
  6. North America Allergy Market, By Region, From 2020 to 2025 (USD Billion)
  7. North America Uveitis Market, By Region, From 2020 to 2025 (USD Billion)
  8. North America Others Market, By Region, From 2020 to 2025 (USD Billion)
  9. North America Ophthalmic Drugs Market, By Therapeutic Class, From 2020 to 2025 (USD Billion)
  10. North America Anti-inflammatory Drugs Market, By Region, From 2020 to 2025 (USD Billion)
  11. North America Anti-infective Drugs Market, By Region, From 2020 to 2025 (USD Billion)
  12. North America Anti-glaucoma Drugs Market, By Region, From 2020 to 2025 (USD Billion)
  13. North America Anti-allergy Drugs Market, By Region, From 2020 to 2025 (USD Billion)
  14. North America Anti-VEGF Agents Market, By Region, From 2020 to 2025 (USD Billion)
  15. North America Others Market, By Region, From 2020 to 2025 (USD Billion)
  16. North America Ophthalmic Drugs Market, By Product Type, From 2020 to 2025 (USD Billion)
  17. North America Prescription Drugs Market, By Region, From 2020 to 2025 (USD Billion)
  18. North America Over-the-Counter Drugs Market, By Region, From 2020 to 2025 (USD Billion)
  19. North America Ophthalmic Drugs Market, By Distribution Channel, From 2020 to 2025 (USD Billion)
  20. North America Hospital Pharmacies Market, By Region, From 2020 to 2025 (USD Billion)
  21. North America Online Pharmacies Market, By Region, From 2020 to 2025 (USD Billion)
  22. North America Independent Pharmacies & Drug Stores Market, By Region, From 2020 to 2025 (USD Billion)
  23. North America Ophthalmic Drugs Market, By Dosage Form, From 2020 to 2025 (USD Billion)
  24. North America Liquid Ophthalmic Drug Forms Market, By Region, From 2020 to 2025 (USD Billion)
  25. North America Solid Ophthalmic Drug Forms Market, By Region, From 2020 to 2025 (USD Billion)
  26. North America Semisolid Ophthalmic Drug Forms Market, By Region, From 2020 to 2025 (USD Billion)
  27. North America Multicompartment Drug Delivery Systems Market, By Region, From 2020 to 2025 (USD Billion)
  28. North America Other Ophthalmic Drug Forms Market, By Region, From 2020 to 2025 (USD Billion)
  29. North America Ophthalmic Drugs Market, By Technology, From 2020 to 2025 (USD Billion)
  30. North America Biologics Market, By Region, From 2020 to 2025 (USD Billion)
  31. North America Cell Therapy Market, By Region, From 2020 to 2025 (USD Billion)
  32. North America Gene Therapy Market, By Region, From 2020 to 2025 (USD Billion)
  33. North America Drug Delivery Market, By Region, From 2020 to 2025 (USD Billion)
  34. North America Small molecule Market, By Region, From 2020 to 2025 (USD Billion)
  35. North America Others Market, By Region, From 2020 to 2025 (USD Billion)
  36. United States Ophthalmic Drugs Market, By Disease Indication, From 2020 to 2025 (USD Billion)
  37. United States Ophthalmic Drugs Market, By Therapeutic Class, From 2020 to 2025 (USD Billion)
  38. United States Ophthalmic Drugs Market, By Product Type, From 2020 to 2025 (USD Billion)
  39. United States Ophthalmic Drugs Market, By Distribution Channel, From 2020 to 2025 (USD Billion)
  40. United States Ophthalmic Drugs Market, By Dosage Form, From 2020 to 2025 (USD Billion)
  41. United States Ophthalmic Drugs Market, By Technology, From 2020 to 2025 (USD Billion)
  42. Canada Ophthalmic Drugs Market, By Disease Indication, From 2020 to 2025 (USD Billion)
  43. Canada Ophthalmic Drugs Market, By Therapeutic Class, From 2020 to 2025 (USD Billion)
  44. Canada Ophthalmic Drugs Market, By Product Type, From 2020 to 2025 (USD Billion)
  45. Canada Ophthalmic Drugs Market, By Distribution Channel, From 2020 to 2025 (USD Billion)
  46. Canada Ophthalmic Drugs Market, By Dosage Form, From 2020 to 2025 (USD Billion)
  47. Canada Ophthalmic Drugs Market, By Technology, From 2020 to 2025 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample